CorMedix announced that the Center for Medicare & Medicaid Services, CMS, has determined that DefenCath qualifies for pass-through status under the hospital Out-Patient Prospective Payment System, OPPS. Pass-through status provides for separate payment under Medicare Part B for the utilization of DefenCath in the out-patient ambulatory setting for a period of at least two years, and up to a maximum of three years.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath
- CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider
- CorMedix announces commercial agreement with dialysis provider
- CorMedix Inc. to Participate in Two Upcoming Investor Conferences
- CorMedix files $150M mixed securities shelf